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Sodium nitroprusside (SNP) has been widely used to control blood pressure in infants
and children. The goals of this analysis were to develop models that describe the
hemodynamic response to SNP dosing in pediatric patients; examine sources of variation
in dose-response, defining age, and size dependencies; and determine vulnerable
populations or patient subtypes that may elicit dosing modifications. A multi-center,
randomized, double-blinded, parallel-group, dose-ranging, effect-controlled study,
followed by an open-label dose titration of an intravenous infusion of SNP was
undertaken in 203 pediatric subjects, who required deliberate hypotension or controlled
normotension during anesthesia. A total of 3464 MAP measurements collected from 202
patients during the study’s blinded phase, including baseline measurements up to 6min
prior to the blinded were available for analysis. A population K-PD model was developed
with a one-compartment model assumed for SNP. Size differences in CL and V of the
effect compartment were described using theory-based allometry. An inhibitory sigmoidal
Emax model was used to describe the effect of SNP. A power function of age was used
to describe age-related differences in baseline MAP. A mixture model of two groups with
low and high EC50 was used to explain variability in MAP response. Change in MAP was
characterized by a linear disease progression slope during the blinded phase. In the final
population model, CL and V increased with weight, and baseline MAP increased with
age. The effect compartment half-life of SNP was 13.4min. The infusion rate producing
50% of Emax (ER50) at steady state for high EC50, was 0.34µg/kg/min and for low EC50
0.103µg/kg/min. The K-PD model well-describes initial dosing of SNP under controlled
circumstances; model-based dosing guidance agrees with current practice. An initial
titration strategy supported via algorithm-based feedback should improve maintenance
of target MAP.
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Introduction
Controlled hypotension, also referred to as deliberate
hypotension, is a technique in general anesthesia in which
a short-acting hypotensive agent is administered to reduce
blood pressure and thus bleeding during surgery. The procedure
facilitates surgery by making vessels and tissues more visible
through reduced blood loss. While the use of general anesthetic
agents or regional anesthesia is an alternative, management
of controlled hypotension with sodium nitroprusside (SNP)
(Degoute, 2007) has been common strategy in pediatrics for
many years. Despite the usage, dosing guidance has been
empirically-based and varies across institutions and practices.
SNP is an effective hypotensive agent used in a variety of
indications including controlled hypotension in children.
Despite its widespread use, there is a paucity of information on
the dose–response relationship. Due to rapid metabolism and
chemical instability and thus a short half-life, the measurement
of SNP plasma concentration for pharmacokinetic (PK) analysis
has not been possible, despite numerous attempts to quantify
the parent compound and metabolites (Pérez-Ruiz et al., 1991;
Vesey et al., 1999). Initial dosing is based on patient weight
with subsequent empirical adjustment of dose (infusion rate and
duration) largely guided by the individual mean arterial pressure
(MAP) response over time.
In support of the Best Pharmaceuticals for Children Act
(BPCA), a multi-center, randomized, double-blinded, parallel-
group, dose-ranging, effect-controlled study, followed by an
open-label dose-titration of an intravenous infusion of SNP
(Drover et al., 2015) has recently been completed. The study
was in response to the written request authored by the Food
and Drug Administration (FDA), pursuant to Section 505A of
the Federal Food, Drug and Cosmetic Act (http://bpca.nichd.
nih.gov/clinical/requests/Documents/sodium_nitroprusside.pdf).
In addition to providing meaningful labeling for pediatric
surgical patients receiving SNP, a model-based approach
to characterize the relevant pharmacokinetic and
pharmacodynamic (PKPD) response to SNP was advocated
in the written request, particularly with the emphasis to provide
dosing guidance. In the absence of an exposure biomarker
(drug and/or metabolite concentration), the primary analysis
was driven by dose–response characterization, where patient
characteristics including indices of size and maturation,
demographics, clinical conduct, and patient status were used
as covariates to explore time-dependent changes in MAP as a
function of the time course of dosing. Hemodynamic variables
collected during this investigation included MAP, systolic, and
diastolic blood pressure, and heart rate.
The objectives of the population-based PKPD analysis were
to: develop model(s) that describe the hemodynamic response to
SNP dosing in pediatric patients; examine sources of variation
in the dose–response relationship, particularly defining age and
size dependencies; determine vulnerable populations or patient
subtypes thatmay elicit dosingmodifications different from those
for the mainstream population; and provide dosing guidance
suitable for labeling, supported by simulations of the likely
variation in MAP response. We present the details of the
hemodynamic K-PD analysis herein, along with simulations
based on the model that assess dosing considerations in children.
Materials and Methods
Study Design
The study (NICHD-2003-09-DR) was a multi-center,
randomized, double-blinded, parallel-group, dose-ranging,
effect-controlled study, followed by an open-label, dose-titration
of an intravenous infusion of SNP in 203 pediatric subjects
(birth to 17 years of age). These subjects required deliberate
hypotension or controlled normotension for an anticipated
duration of at least 2 h1. The design and support for the study
resulted from the BPCA. The details of the study design and
initial dosing and subsequent dosing titration are presented in a
companion manuscript (Drover et al., 2015).
Any patient who had the first blood sample for PK analysis
collected during the blinded study drug administration period or
who discontinued blinded study drug was considered complete
for analysis because:
• MAP fell below 50mm Hg (40mm Hg for neonates), or
• Heart rate exceeded the age-adjusted maximum (Drover et al.,
2015), or
• An adverse event occurred that was judged possibly or
probably related to the study drug.
At least one hundred (≥50%) of these patients were targeted to
be pre-pubertal (<Tanner stage 3), with at least 50% of them
being neonates (post-natal age less than 1 month or infants (from
1 month to <2 years of age). In order to qualify for inclusion,
neonates were required to be full-term gestation and have a
weight of ≥2.5 kg.
Briefly, after their anesthesia and measurement of vital
signs were stabilized, subjects began the blinded study drug
administration period (dose-ranging). During this phase,
subjects were randomized in equal proportions to receive SNP at
one of four doses: 0.3, 1.0, 2.0, or 3.0µg/kg/min, administered
as a continuous intravenous infusion for up to 30min. Dose
titrations were made during the double-blind study drug
administration period to minimize the potential risk of excessive
drop in blood pressure to study participants. During titration
to the targeted rate, the investigator was requested to keep the
previously titrated rate constant for the remainder of the 30min,
if clinically acceptable. Following 30min of blinded study drug
administration, an open-label titration of the study drug was
initiated until blood pressure control was achieved (Drover et al.,
2015). Dose increments of 0.1–1.0µg/kg/min were utilized with
the desire to control target MAP (effect-control dosing). The
total duration of observation was up to 180min during this
phase, and rescue medication was allowed. The follow-up period
was to end 24 h after completion of the study drug administration
phase or hospital discharge, whichever occurred first.
1Study Protocol Number: NICHD-2003-09-DR (NITPIC 1.0). Phase II, A
Multicenter, Randomized, Double-blinded, Parallel Group, Dose-ranging, Effect-
controlled Study to Determine the Pharmacokinetics and Pharmacodynamics of
Sodium Nitroprusside in Pediatrics Subjects. 2004.
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Drug Administration
Infusion pumps capable of reliable delivery at low infusion rates
(to 0.1mL/h) were used to administer SNP. All syringe pumps
had free flow protection. Captured syringe type infusion pumps
had been internally calibrated for accuracy by the manufacturer
and verified by each site as part of an equipment management
program. Quality-assurance checks were performed periodically
according to manufacturer specifications. Microbore low-
compliance tubing, with volumes of approximately 1mL or less
was used. The infusate syringe was covered with an amber or
opaque plastic wrap to protect the drug from light.
The study drug was infused via either a dedicated peripheral
intravenous catheter or a dedicated lumen of a multi-orifice,
central-venous catheter. Catheters were chosen to minimize dead
space in order to ensure rapid, accurate delivery of the drug
to the subject. The study drug was administered along with a
carrier fluid such that the carrier fluid was infusing at a minimum
of 10mL/h, further eliminating the dead space issue. Carrier,
blinded drug, and open-label drugs were attached and flushed
through a 2-tailed T-piece connector such that there was no time
delay in switching from blinded to open-label infusion, as well
as to add no further dead space to the tubing before the invasive
catheter.
PKPD Data
Due to low concentrations resultant from a short half-life, rapid
metabolism, and chemical instability, the measurement of SNP
concentration in plasma was not possible (Kazim et al., 1996).
Analyses of cyanide, thiocyanate, methemoglobin, lactic acid,
and arterial blood-gas analysis with co-oximetric analysis were
performed throughout the trial to indirectly monitor sodium
nitroprusside exposure. The measurement of cyanide in plasma
employing a classical UV bioanalytical method was provided by
National Medical Services, Inc. (NMS Labs). All of the cyanide
specimens collected had measured values that were below the
assay limit of detection (0.10µg/mL).
The mean arterial pressure (MAP) was the primary response
and declared efficacy endpoint investigated in this trial. Other
hemodynamic response variables (systolic and diastolic blood
pressure and heart rate) were also measured. This analysis is
focused on MAP response.
The MAP was recorded:
• Immediately prior to and every 15min after the initiation of
anesthesia until the blinded study drug was initiated.
• Immediately prior to and every 2min for 30min after the
initiation of the blinded study drug.
• If the open-label study drug did not start immediately after
the end of the blinded study drug infusion, every 2min for
10min, then every 5min for 20min, and then every 15min
until open-label infusion started.
• Immediately prior to and every 2min for 10min after the
initiation of the open-label study drug and any rate change of
open-label and then every 5min throughout the duration of
the study drug administration.
• Immediately before, and every 2min for the first 10min
after the study drug was discontinued and then every
5min for the next 20min, for a total of 30min after
discontinuation.
• Every 2min for 10min following the start of an adverse
event that was possibly or probably related to the study drug,
followed by every 5min for the duration of the adverse events
(AE), then every 5min for 30min upon resolution of the
adverse event.
Analysis Datasets
The dataset from the blinded phase was used for model
development, and the dataset from the open-label phase was used
for model evaluation (Mentre and Escolano, 2006; Brendel et al.,
2007). Differences between the two phases with regards to the
analysis datasets are aligned with the objectives of each study
phase.
Only the MAP baseline values measured within 6min prior
to the initiation of the blinded phase were included in model
construction. While creating analysis datasets, certain subject
and/or MAP measurement records were excluded for one or
more of the following reasons: (1) there was no dose information,
(2) the time was not recorded, (3) data were deemed inaccurate
by the investigator.
All data preparation and presentation were performed with
either the SAS software, version 9.2, or R software, version 2.8.1.
The analysis was completed using NONMEM software, version
6.2 (ICON Development Solutions).
Model Assessment and Workflow
The minimum value of the objective function (OFV), computed
in NONMEM for each analysis, was used to evaluate and
compare models in a hierarchical manner. The difference in
OFV was considered to be chi-square distributed for the purpose
of hypothesis-testing. The goodness-of-fit of each NONMEM
analysis was assessed by the examination of the following
criteria: (a) agreement in scatterplots of predicted and individual
predicted values vs. measured values; (b) lack of trend or pattern
in scatterplots of residuals and weighted residuals vs. predicted
values; and (c) lack of trend or pattern in scatterplots of residuals
and weighted residuals vs. predicted values.
The population analysis for SNP performed on the blinded
phase dataset included all baseline values in the following
sequence of steps: MAP baseline value assessment, structural K-
PDmodel development, random-effect model development, final
parameter-estimation, and model evaluation. The estimation
methods, including the first-order conditional estimation
method (FOCE) and the FOCE with interaction method
(FOCE-I), were evaluated at various stages of the development
process. NONMEM analyses were performed on a Microsoft
Windows (XP) operating system. The g77 (version 0.5.25)
FORTRAN compiler was used to create NONMEM executable
files. Wings for NONMEM (Holford, 1996) was used to produce
bootstrap results.
Structural K-PD Model Development
A K-PD model approach (Jacqmin et al., 2007; Holford,
2010) was utilized for this analysis, given the lack of plasma
concentration data. With this approach, the MAP response as
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a function of biophase exposure is defined by the time course
of drug input (dose). SNP concentrations are predicted on
the basis of a one-compartment model representing the effect
compartment. The effect compartment was assumed to have a
nominal volume of distribution (V) of 1 L/70 kg. The clearance of
the effect compartment (CL) was derived based on this assumed
volume. The drug concentration in the effect compartment
(Ce) is estimated based on the assumption of an instantaneous
relationship between Ce and the predicted response (MAP in
this case). Allometric scaling on effect-compartment parameters,
the clearance (CL) and the volume of distribution (V), were
employed to account in a biologically plausible fashion for
differences in the time course of Ce associated with weight
(Anderson and Holford, 2008; Holford, 2010) based on allometry
theory.
PD Model
An inhibitory sigmoidal Emax model was used initially. Logistic
transformation was employed to constrain the fractional change
in Emax, relative to E0, to be from 0 to 1. The examination of
the parameter distributions of the starting model revealed that
there were two subpopulations of EC50 and Emax. A mixture
model on EC50 fitted the data better than the mixture model on
Emax. Therefore, the mixture model on EC50, low EC50, and high
EC50 was selected for further model development. Regarding
the natural disease-progression model, the use of a linear model
improved the model fit. Age was associated with higher baseline
MAP. PD equations of the model are provided below.
MAPij =
{
S0, i−Emax,i • C
γ
e, ij/(High_EC
γ
50,i + C
γ
e, ij)
S0, i−Emax,i • C
γ
e, ij/(Low_EC
γ
50,i + C
γ
e, ij)
+ α • Time (1)
S0, i = S0, i
(
Agei
Median Age
)PwrAge
(2)
where MAPij, the MAP at jth time in the ith individual; S0,i,
the baseline MAP in the ith individual; Emax,i, maximal effector
maximal decrease of MAP in the ith subject; Ce,ij, SNP effect
compartment concentration at jth time in the ith subject; EC50,i,
nominal SNP concentration or SNP concentration in effect
compartment in the ith subject that leads to 50% of the effect; γ,
Hill coefficient for the sigmoidal Emax function; Agei, the post-
natal age for the ith subject; PwrAge, the power function of
age.
Between-subject variability (BSV) of V, CL, S0, Low EC50,
High EC50, and Emax was modeled using an exponential random-
effect model. The linear disease-progression slope was based
on a proportional random-effects model permitting positive or
negative individual slope values (Chan and Holford, 2001). A
non-parametric bootstrap involving 1000 replicates was used to
create the bootstrap distribution of the parameters. The bootstrap
average and 95% confidence interval for each parameter was
estimated from the bootstrap distribution.
Model Evaluation
A visual predictive check (VPC), based on the premise that a
model and parameters derived from the observed data set should
produce simulated data similar to the original observed data, was
utilized to evaluate the adequacy of the final model. One hundred
replicates of the original dataset were simulated, based on the
final model, and a 95% confidence interval, based on simulated
datasets, was computed for the 5th, 50th, and 95th percentiles.
Percentiles of observed and predicted values were constructed in
order to compare the ability of the model to predict the median
and 90% interval.
Simulations
Simulations were performed to examine dosage regimens of SNP
that mimic typical patient settings and clinical objectives. Two
clinical scenarios were considered:
Scenario 1
The objective of this simulation was to find doses to achieve the
MAP reduction of a certain value (10 and 15mm Hg) within
a clinically-relevant time frame (assumed 5min). Hypothetical
patients with different age/weight designation were included.
Tanner age strata were considered, and a median age/weight for
each stratum was used when considering hypothetical patients.
The median age/weight for each stratum was calculated from
the data used for the model development. Since there are two
subpopulations identified in the model, more sensitive to SNP
(low EC50) and less sensitive (high EC50) groups were examined
as well.
Scenario 2
The objective of this simulation was to the find an initial dose
to reduce MAP to the certain target value (assumed 60mm Hg)
within 3min, and then to identify a second dose to maintain
MAP at that value for 30min.
Simulations ignoring variability (deterministic) and
incorporating variability (stochastic) were performed.
Deterministic simulations were based on the population
predicted values from the final model, whereas stochastic
simulations (not shown), based on 100 replicates per scenario,
used the full variance-covariance matrix.
Results
Analysis Dataset
A total of 203 patients enrolled in the study and total of 3038
MAP measurements obtained from 202 patients were available
for the model-building analysis. For the open-label portion of the
study, a total of 10,671 MAP measurements were available from
203 subjects. By applying the same criteria (as for the blinded
study data), a total of 10,303 MAP measurements were available
from 197 patients for the qualification/validation analysis.
Summary statistics of subject demographic characteristics,
dosing data, and MAP measurements are summarized in
Table 1.
Population K-PD Model
Parameter estimates and standard errors for the final population
K-PDmodel are provided inTable 2. The infusion rate producing
50% of Emax (ER50) at steady state was calculated from the
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TABLE 1 | Summary statistics of variables included in model development
dataset.
Variable Continuous variables
Mean Median Min Max
DOSE VARIABLES
Dose rate (µg/kg/min) 0.87 0.66 0.09 3.04
Infusion duration (min) 8.61 5 1 30
PD VARIABLE
MAP (mm Hg) 69.4 68 29 143
DEMOGRAPHIC VARIABLESa
Age (y) 8.83 11.3 0.01 17.01
Weight (kg) 33.8 31.6 2.8 112.2
Categorical variables
N (%)
Gender
Male 73 (36)
Female 129 (64)
Race
American Indian 13 (6.4)
Asian 7 (3.5)
Black 16 (7.92)
Pacific Islander 1 (0.5)
White 164 (81.2)
Other 1 (0.5)
Ethnicity
Hispanic 47 (23.3)
Not Hispanic 155 (76.7)
FDA Age Categoryb
Neonates 4 (2)
Infants 51 (25.2)
Children 47 (23.3)
Adolescents 100 (49.5)
Development strata for enrollment
Birth to <30 days 4 (2)
30 days to <2 years 51 (25)
2 to <6 years 12 (6)
6 yrs to Tanner Stage III 43 (21)
Tanner Stage III to <17 years 92 (46)
aNo of Subjects = 202.
bPer FDA Guidance (General Clinical Pharmacology Considerations for Pediatric Studies
for Drugs and Biological Products: Guidance for Industry, www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/guidances/ucm425885.pdf).
product of the population standard values of EC50 and CL.
All parameters were generally well-estimated with reasonable
precision (RSE< 25%), except for the between subject variability
of high EC50 (RSE = 74.3%), and low EC50 (RSE = 72.0%).
The goodness-of-fit plots for final model (Figures 1, 2) overall
indicated that there were no strong biases in the fit of this model
to the data.
The final covariate models for computing CL, V, and S0 of
the final population model are provided in Equations (3–5)
below.
CLi (L/h/70kg) = 3.13 •
(
WTi
70
)0.75
(3)
Vi
(
L/70kg
)
= 1 •
(
WTi
70
)
(4)
S0, i
(
mmHg
)
= 76 •
(
Agei
11.33
)0.0338
(5)
The calculated effect compartment half-life of SNP was 13.4min.
The ER50 for groups with low and high EC50 was 0.103 and
0.34µg/kg/min. ER50 is an infusion rate producing 50% of
Emax at steady state. It was calculated from the product of
nominal EC50 and CL. MAP increased over time, independent
of SNP exposure. Baseline MAP (S0) increased with post-natal
age. Residual variability was estimated to have a co-efficient of
variation of 33.2%.
Model Evaluation
The goodness-of-fit plots from the application of final model
to the open-label phase data are presented in Figures 1A–D.
The population predictions were high relative to the observed
values. The visual predictive check shown in Figures 2A–C
adequately describes the median and 95th percentile of observed
MAP during the double-blind phase. The 5th percentile of
predicted MAP was lower than observed at later times, likely
due to homeostatic responses produced by low MAP, leading to
tolerance. Figures 3A–B shows the application of the final model
constructed from the blinded phase data to the open phase data
(Figure 3A) and the visual predictive check applied to the open
phase data (Figure 3B). Deviations from the extremes are most
likely resultant from the unaccounted for (in the blinded phase
model) procedures permitted during the open-label phase.
Simulation Scenarios
Simulation 1
This simulation was based on five hypothetical patients
(age/weight: 0.035 years/3.615 kg, 0.58 years/7.955 kg, 4.545
years/16.15 kg, 10.93 years/34.2 kg, and 14.8 years/52.6 kg)
receiving a single administration of SNP. The simulation results
reflect the median weight associated with each of the 5 age strata
in the current trial. Due to the association of age with baseline
MAP, the baseline MAP values are necessarily different for each
hypothetical patient. The baseline MAP values for hypothetical
patients of ages 0.035, 0.58, 4.545, 10.93, and 14.8 years are
63, 69, 74, 76, and 77mm Hg, respectively. Figures 4A,B shows
the MAP time course based on SNP dosing required to reduce
MAP 10mmHg (Figure 4A) and 15mmHg (Figure 4B) for each
hypothetical patient. For the low EC50 subpopulation, the doses
needed for the 10mm Hg reduction of MAP for hypothetical
patients are 0.432, 0.393, 0.372, 0.354, and 0.346µg/kg/min,
respectively. For the high EC50 subpopulation, the doses needed
for the 10mm Hg reduction of MAP for hypothetical patients
are 1.88, 1.71, 1.62, 1.55, and 1.51µg/kg/min, respectively. For
the low EC50 subpopulation, the doses needed for the 15mm
Hg reduction of MAP for hypothetical patients are 0.537,
0.465, 0.427, 0.415, and 0.407µg/kg/min, respectively. For the
high EC50 subpopulation, the doses needed for the 10mm Hg
Frontiers in Pharmacology | www.frontiersin.org 5 July 2015 | Volume 6 | Article 151
Barrett et al. SNP hemodynamic model for children
TABLE 2 | Parameter estimates and standard errors for the final K-PD model.
Parameter Population parameters Magnitude of BSV
Estimate Bootstrap %RSE Bootstrap average (%CV)d Bootstrap %RSE
Modela Bootstrap averageb
V (L/70 kg) 1 (FIXED) 1 (FIXED) NA 82.0 7.6
CL (L/h/70 kg) 3.12 3.13 9.6 62.7 16.1
S0(mm Hg) 76 76 1.0 13.2 5.4
Power of age on S0 0.0333 0.032 19.2
Emax (mm Hg)e 22.65 21.9 7.6 76.5 13.7
Probability of high EC50 subpopulation 0.699 0.701 8.8
EC50 (µg/L)—High 460 458 10.3 10.8 74.3
EC50 (µg/L) —Low 138 104.3 21.6 22.1 72
Hill coefficient 7.23 7.27 11.2
Disease-progression slope (mm Hg) 12.3 11.0 19 211 19.3
ER50 (mg/h/70 kg)—High
c 1.435 0.33 24.1
ER50 (mg/h/70 kg)—Low
c 0.431 1.42 14.2
Residual variability (%CV) 32.9 33.2 3.7
aThe parameter estimates were obtained from final model using NONMEM.
bThe estimates were obtained from the bootstrap distribution.
cER50 at steady state was calculated from the product of nominal EC50 and CL.
dCV% is the apparent coefficient of variation obtained from the square root of the estimate of the variance of between subject variability.
eBSV of Emax used a logistic transformation of the random effect to constrain the value between 0 and E0.
FIGURE 1 | (A–D) Diagnostic plots from final SNP K-PD hemodynamic
model constructed from blinded phase data for low and high MAP
response groups: (A) Low EC50 population-predicted vs. observed, (B)
High EC50 population-predicted vs. observed, (C) Low EC50
individual-predicted vs. observed, and (D) High EC50 individual-predicted
vs. observed.
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FIGURE 2 | (A–C) Visual predictive check plots based on the final SNP K-PD
hemodynamic model: (A) observed MAP response with 5th, 50th, and 95th
percentiles, (B) predictions and prediction intervals for low EC50 group, and
(C) predictions and prediction intervals for high EC50 group.
reduction of MAP for hypothetical patients are 2.38, 2.01, 1.86,
1.77, and 1.73, respectively. These simulated dosing requirements
are summarized in Table 3.
Simulation 2
The results from the staggered dosing simulation were based on
the same five hypothetical patient characteristics as in simulation
1. For convenience, in Figures 5A,B, we have shown only the
MAP response in a representative patient of 7 months weighing
8 kg under both low and high EC50 conditions. Target MAP for
FIGURE 3 | Scatterplot of observed MAP with 5th, 50th, and 95th
percentiles (A) and visual predictive check based on applying the final
SNP K-PD hemodynamic model to the open (unblinded) phase MAP
response (B).
all hypothetical patients was assumed to be the same (60mmHg).
In all cases, the first dose was needed to get to the target MAP
within 3min, and the second dose was needed to maintain MAP
at the target for 30min. For the low EC50 subpopulation, the
first dose for 7 month (0.58 years) patient was 0.566µg/kg/min
and the second dose was 0.158µg/kg/min. For the high EC50
scenario, the first dose was 2.472µg/kg/min, and the second dose
was 0.691µg/kg/min.Table 4 contains the summary of simulated
dosing requirements for the staged infusion regimens for all 5 age
strata for both low and high EC50 subpopulations.
Discussion
A hemodynamic model for MAP response to intravenous
infusion of SNP for the purpose of controlled intraoperative
hypotension in children is presented. Given the absence of
concentration data, a population kinetic-pharmacodynamic (K-
PD) model was employed to investigate the relationship between
Frontiers in Pharmacology | www.frontiersin.org 7 July 2015 | Volume 6 | Article 151
Barrett et al. SNP hemodynamic model for children
FIGURE 4 | Simulation-based (deterministic) dose* prediction for Low (A) and High (B) EC50 response groups to achieve target MAP across age strata
(targeted reduction of 10mm Hg within 5min).
SNP doses, time, and MAP response. The final model fitted
the data obtained during the blinded phase following SNP
administration including the MAP baseline measurements,
reasonably well.
The over-prediction of MAP in the open blind phase reflects
the use of procedures to change MAP not included in the model
(based on the blinded phase data) used to make predictions.
Several factors, such as pain (e.g., at the time of surgical incision
of other manipulation), anesthesia, and excitement, may affect
blood pressure. These factors were not recorded and therefore
not accounted for in the model.
Most importantly, the parameter estimates seem to be
plausible, given the assumed pharmacokinetic attributes of
SNP. Specifically, the estimated effect compartment half-life is
consistent with the extensive and rapid metabolism appreciated
for SNP (Przybylo et al., 1995; Kazim et al., 1996). Likewise, the
confirmation of baseline MAP increase with post-natal age is
consistent with physiologic expectations. Baseline MAP values
are most likely affected by the anesthesia at the beginning of the
blinded phase.
In clinical practice, the SNP dose is initially based on patient
weight; dose recommendations are based on weight because of
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the expected association of weight with SNP CL and V (Sinaiko,
1996; Tobias, 2002). It should be appreciated that the relationship
between clearance and weight is not linear, however. As clearance
is most important for maintaining concentrations, changes in
weight with age necessitate that a fixed dose per kg cannot be
used for all age groups. This is a fundamental property of theory-
based allometry that was used in this analysis. The allometric
scaling of effect-compartment clearance is expected to scale with
an exponent of ¾ reflecting not only metabolism but also blood
flow-dependent distribution to tissues.
TABLE 3 | Dosing recommendation: single SNP infusion of 5min.
Age (y)/ Baseline MAP Target MAP Low EC50 High EC50
Weight (kg) (mm Hg) reduction (mm Hg) (µg/kg/min) (µg/kg/min)
0.035/3.615 62.6 10 0.432 1.88
0.58/7.955 68.8 10 0.395 1.72
4.545/16.15 73.7 10 0.372 1.62
10.93/34.2 75.9 10 0.354 1.55
14.8/52.6 76.7 10 0.346 1.51
0.035/3.615 62.6 15 0.537 2.38
0.58/7.955 68.8 15 0.465 2.01
4.545/16.15 73.7 15 0.427 1.86
10.93/34.2 75.9 15 0.415 1.77
14.8/52.6 76.7 15 0.407 1.73
Efforts were made to identify a maturation process associated
with age that might be reflected in the apparent effect-
compartment clearance. Despite the inclusion of infants and
neonates in the patient population, there was no evidence for a
change in clearance with age independently of size. We speculate
this is because the chemical breakdown of SNP is not dependent
on liver or kidney size, and thus there will be no maturation of
metabolism associated with growth of these organs.
Although SNP is an old drug and its use is widespread, there
is no accepted guidance for SNP dosing; labeling statements
regarding dosing guidance for 5 age groups were derived from
simulations using the final model. Nevertheless, as the model
was developed in pediatric patients under anesthesia, parameter
estimates (S0 and Emax) in other settings may vary due to the
influence of concomitant medications and procedures.
It is important to acknowledge that we have identified two
groups of patients—those with a lowC50 who need a low dose and
those with a high C50 who need a higher dose. We were unable to
distinguish any way to predict these two levels of sensitivity, on
the basis of study data collected. A prudent approach is to assume
all patients have low C50, then adjust dose higher if the response
is not as expected.
Based on the simulation exercise, the reduction in MAP
following SNP administration can be managed with a small
number of dose adjustments. While hemodynamic improvement
should be considered in conjunction with other meaningful
TABLE 4 | Dosing recommendation: sequential SNP infusions of 5 and 30min.
Age (y)/ Baseline MAP Target MAP Low EC50 First/Second High EC50 First/Second
Weight (kg) (mm Hg) reduction (mm Hg) infusion (µg/kg/min) infusion (µg/kg/min)
0.035/3.615 62.6 2.6 0.479/0.164 2.118/0.718
0.58/7.955 68.8 8.9 0.577/0.158 2.472/0.691
4.545/16.15 73.7 13.7 0.617/0.163 2.683/0.722
10.93/34.2 75.9 15.9 0.635/0.195 2.778/0.828
14.8/52.6 76.7 16.7 0.640/0.206 2.744/0.951
FIGURE 5 | Simulation-based (deterministic) two-stage infusion
dose* prediction for Low (A) and High (B) EC50 response to
achieve a target MAP of 60mm Hg within 3min and maintaining
this level for 30min. The simulation is based on the response in a
representative (virtual) patient of 7 months weighing 8 kg. Shaded areas
refer to infusion durations.
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clinical outcomes when assessing the overall efficacy of SNP, it
is clear that a model-based approach may improve the tendency
to “over-adjust” or too frequently titrate SNP in response to real
time MAP (Spielberg et al., 2014). Parallel efforts to discriminate
superior dosing practices in this investigation revealed much
variability in dosing practice, with hemodynamic control
well-outside of anticipated patient management expectations
(Spielberg et al., 2014).
Indices of toxicity were not included in the analysis. Incidence
of toxicity in this study was actually quite low (Drover et al.,
2015). Similarly, as suggested doses from simulations are based
on achievement of MAP targets, they may not reflect optimal
doses, given the absence of toxicity information. Recently
approved dosing guidance provided in the Federal Register states
that “a starting dose of 0.3µg/kg/min is reasonable,” based on
the pooled dataset (HHS FDA, 2014). Indeed, based on current
clinical practice, this is certainly a reasonable starting point and
does bisect model-based recommendations. Hopefully, future
evaluations will consider the clinical benefit of a more effectively
managed patient (greater percentage of time within an acceptable
target MAP range) as opposed to an empirical-based standard of
care.
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